RhumbLine Advisers’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.3M Sell
303,881
-4,308
-1% -$24K ﹤0.01% 2064
2025
Q4
$2.76M Sell
308,189
-1,997
-0.6% -$12.4K ﹤0.01% 1698
2025
Q3
$1.15M Buy
310,186
+12,700
+4% +$34.6K ﹤0.01% 2170
2025
Q2
$580K Buy
297,486
+47,561
+19% +$99.1K ﹤0.01% 2595
2025
Q1
$440K Sell
249,925
-13,880
-5% -$31.6K ﹤0.01% 2654
2024
Q4
$702K Sell
263,805
-2,578
-1% -$6.64K ﹤0.01% 2453
2024
Q3
$610K Buy
266,383
+5,444
+2% +$16.6K ﹤0.01% 2570
2024
Q2
$762K Buy
260,939
+53,389
+26% +$163K ﹤0.01% 2394
2024
Q1
$755K Sell
207,550
-2,747
-1% -$5.28K ﹤0.01% 2417
2023
Q4
$318K Sell
210,297
-3,949
-2% -$5.08K ﹤0.01% 2935
2023
Q3
$287K Sell
214,246
-185,963
-46% -$310K ﹤0.01% 2954
2023
Q2
$720K Buy
400,209
+228,478
+133% +$388K ﹤0.01% 2468
2023
Q1
$285K Sell
171,731
-2,598
-1% -$5.27K ﹤0.01% 2631
2022
Q4
$335K Buy
174,329
+2,499
+1% +$5.06K ﹤0.01% 2635
2022
Q3
$385K Buy
171,830
+9,431
+6% +$26.9K ﹤0.01% 2615
2022
Q2
$526K Sell
162,399
-252
-0.2% -$1.1K ﹤0.01% 2478
2022
Q1
$856K Buy
162,651
+12,174
+8% +$68.4K ﹤0.01% 2192
2021
Q4
$1.28M Buy
150,477
+98,100
+187% +$902K ﹤0.01% 2107
2021
Q3
$521K Buy
52,377
+17,730
+51% +$161K ﹤0.01% 2523
2021
Q2
$323K Buy
+34,647
New +$395K ﹤0.01% 2758

Other funds holding NUVB

RhumbLine Advisers's NUVB Position: Q1 2026 in Review

RhumbLine Advisers reduced its Nuvation Bio (NUVB) stake by 1.4% in Q1 2026, selling an estimated $24K and leaving 303,881 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2064.

RhumbLine Advisers first reported a position in NUVB in Q2 2021 and has held it in 20 quarters since. The position peaked at $2.76M in Q4 2025. 231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • RhumbLine Advisers held 303,881 shares of Nuvation Bio worth $1.3M as of Q1 2026.
  • RhumbLine Advisers sold 4,308 Nuvation Bio shares in Q1 2026, an estimated $24K.
  • Nuvation Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2064 holding.
  • RhumbLine Advisers first reported a position in Nuvation Bio in Q2 2021 and has held it in 20 quarters since.
  • RhumbLine Advisers's Nuvation Bio position peaked at $2.76M in Q4 2025.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.